Shares of Gemphire Therapeutics Inc (NASDAQ:GEMP) have been given a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.

Brokers have set a 1 year consensus price objective of $19.00 for the company and are expecting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned Gemphire Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of equities research analysts have recently weighed in on GEMP shares. RBC Capital Markets started coverage on Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued an “outperform” rating and a $25.00 price objective on the stock. Laidlaw started coverage on Gemphire Therapeutics in a research report on Tuesday, September 6th. They issued a “buy” rating and a $20.00 price objective on the stock. Royal Bank Of Canada started coverage on Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued an “outperform” rating and a $25.00 price objective on the stock. Jefferies Group started coverage on Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Canaccord Genuity started coverage on Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued a “buy” rating and a $17.00 price objective on the stock.

Shares of Gemphire Therapeutics (NASDAQ:GEMP) traded up 1.490% during midday trading on Tuesday, reaching $10.149. The company had a trading volume of 4,288 shares. Gemphire Therapeutics has a one year low of $8.80 and a one year high of $13.98. The company’s market capitalization is $94.08 million. The company has a 50-day moving average price of $10.78 and a 200 day moving average price of $10.78.

In other Gemphire Therapeutics news, CFO Jeffrey S. Mathiesen acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, August 10th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $40,000.00. Following the transaction, the chief financial officer now owns 3,927 shares in the company, valued at $39,270. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Steven R. Ph.D. Gullans acquired 500,000 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of dyslipidemia. It is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

5 Day Chart for NASDAQ:GEMP

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.